MedTrace Logo

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

NCT05779995 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2025-08-17

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China

Conditions

  • RSV Infection

Interventions

DRUG

XW001

Inhalation solution

DRUG

Placebo

Inhalation solution with matched volume

Sponsors & Collaborators

  • Hangzhou Sciwind Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hanmin Liu, Dr · West China Second University Hospital

  • Qin Yu · West China Second University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2023-10-10
Completion
2024-01-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779995 on ClinicalTrials.gov